Detalhe da pesquisa
1.
Albuminuria-lowering effect of adding semaglutide on top of empagliflozin in individuals with type 2 diabetes: A randomized and placebo-controlled study.
Diabetes Obes Metab
; 26(1): 54-64, 2024 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-37722966
2.
Overall and inter-individual effect of four different drug classes on soluble urokinase plasminogen activator receptor in type 1 and type 2 diabetes.
Diabetes Obes Metab
; 25(11): 3152-3160, 2023 11.
Artigo
Inglês
| MEDLINE | ID: mdl-37417375
3.
Circulating metabolites and molecular lipid species are associated with future cardiovascular morbidity and mortality in type 1 diabetes.
Cardiovasc Diabetol
; 21(1): 135, 2022 07 18.
Artigo
Inglês
| MEDLINE | ID: mdl-35850688
4.
Urinary peptidome and diabetic retinopathy in the DIRECT-Protect 1 and 2 trials.
Diabet Med
; 38(9): e14634, 2021 09.
Artigo
Inglês
| MEDLINE | ID: mdl-34228837
5.
Visit-to-visit variability of clinical risk markers in relation to long-term complications in type 1 diabetes.
Diabet Med
; 38(5): e14459, 2021 05.
Artigo
Inglês
| MEDLINE | ID: mdl-33179275
6.
Performance of new and panel CKD-EPI equations in European adults with type 2 diabetes.
Diabetes Obes Metab
; 26(6): 2501-2504, 2024 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-38449081
7.
Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open-label, crossover trial.
Diabetes Obes Metab
; 25(10): 3064-3067, 2023 10.
Artigo
Inglês
| MEDLINE | ID: mdl-37385968
8.
The effect of liraglutide on cardiac autonomic function in type 2 diabetes: A prespecified secondary analysis from the LIRAFLAME randomized, double-blinded, placebo-controlled trial.
Diabetes Obes Metab
; 24(8): 1638-1642, 2022 08.
Artigo
Inglês
| MEDLINE | ID: mdl-35415938
9.
Circulating metabolomic markers in association with overall burden of microvascular complications in type 1 diabetes.
BMJ Open Diabetes Res Care
; 12(2)2024 Apr 11.
Artigo
Inglês
| MEDLINE | ID: mdl-38604732
10.
Presence of retinopathy and incident kidney and cardiovascular events in type 2 diabetes with normoalbuminuria - A post-hoc analysis of the PRIORITY randomized clinical trial.
J Diabetes Complications
; 37(4): 108433, 2023 04.
Artigo
Inglês
| MEDLINE | ID: mdl-36841085
11.
Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor.
Front Pharmacol
; 13: 799915, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-35571091
12.
Baseline risk markers and visit-to-visit variability in relation to kidney outcomes - A post-hoc analysis of the PERL study.
Diabetes Res Clin Pract
; 193: 110119, 2022 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-36265753
13.
Effect of liraglutide on expression of inflammatory genes in type 2 diabetes.
Sci Rep
; 11(1): 18522, 2021 09 17.
Artigo
Inglês
| MEDLINE | ID: mdl-34535716
14.
Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [64Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial.
Front Endocrinol (Lausanne)
; 12: 790405, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-34917038
15.
Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial.
BMJ Open Diabetes Res Care
; 9(1)2021 09.
Artigo
Inglês
| MEDLINE | ID: mdl-34518158
16.
Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes.
Diabetes Care
; 42(6): 1112-1119, 2019 06.
Artigo
Inglês
| MEDLINE | ID: mdl-30885954
17.
Soluble urokinase plasminogen activator receptor, platelet aggregation, and carotid plaque thickness in diabetes: A cross-sectional analysis.
J Diabetes Complications
; 38(1): 108654, 2024 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-38042098
18.
Urinary tubular biomarkers as predictors of kidney function decline, cardiovascular events and mortality in microalbuminuric type 2 diabetic patients.
Acta Diabetol
; 55(11): 1143-1150, 2018 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-30105469